Latest News
2013-03-27
CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer
CureVac beginnt klinische Phase 2b Studie seines mRNA-basierten Krebsimpfstoffs bei Patienten mit kastrationsresistentem Prostatakrebs
2012-11-26
Data Published in Nature Biotechnology Show Messenger (m)RNA
Prophylactic Vaccines Based on CureVac's RNActive® Technology
Demonstrate Immunogenicity and Protection Against Influenza
Virus Infection
2012-09-18
CureVac Secures €80 Million in Series D FinancingCureVac erhält 80 Millionen Euro in weiterer Finanzierungsrunde
2011-11-15
CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project co-funded by the U.S. Defense Advanced Research Projects AgencyCureVac gibt Zusammenarbeit mit Sanofi Pasteur im Rahmen eines 33,1 Mio. Dollar Projektes bekannt
2011-11-07
CureVac presents results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA based cancer vaccine, at the 26th Annual SITC Meeting in WashingtonCureVac präsentiert vielversprechende Ergebnisse einer Phase I / IIa-Studie mit dem mRNA-basierten Krebsimpfstoff CV9201 an Patienten mit nicht-klein- zelligem Lungenkrebs (NSCLC)
2011-10-06
CureVac presents promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference
CureVac präsentiert neue vielversprechende Daten für Prostatakrebsimpfstoff CV9103 und Lungenkrebsimpfstoff CV9201 auf der Onkologie-Konferenz ASCO
Archive press here.
Contact
Give us a call or send an email for further information:
T +49 7071.92053-61
T +49 7071.92053-61
CureVac in the Press
2013-04-18: Ernst & Young Biotech-Report 20132013-04-05: FAZ
2012-12-23: Scientific American Guest Blog
2012-12-20: SciBx
2012-12-06: Bloomberg Businessweek
2012-10-15: Der SPIEGEL
2012-09-26: Biotechnologie.de
2012-09-18: Handelsblatt
2012-01-25: Technology Review
Upcoming Conferences
CureVac will be presenting at the following events:May 14 – 15, 2013:
Deutsche Biotechnologietage; Stuttgart, Germany
May 21 – 22, 2013:
Sachs Cancer Biopartnering Forum; Boston, USA
May 22 – 23, 2013:
BioEquity, Stockholm, Sweden
June 3 – 5, 2013:
4th Annual Vaccine Development & Production Summit; Durham, USA
July 1 – 3, 2013:
Handelsblatt Jahrestagung; Düsseldorf, Germany
July 8 – 10, 2013:
11th Vaccines Research and Development Conference; Boston, USA
July 29 – 31, 2013:
3rd International Conference on Vaccines & Vaccination; Las Vegas, USA
August 13 – 15, 2013:
8th annual Novel Vaccines: Innovations & Adjuvants Conference; Boston, USA
October 3 – 4., 2013:
Cancer Vaccines and Gene Therapy Meeting; Malvern, USA